ESA Hyporesponsiveness Linked to Abnormal FGF23 Levels
In a study, hemodialysis patients with the highest and lowest FGF23 levels had higher risks for ESA hyporesponsiveness.
In a study, hemodialysis patients with the highest and lowest FGF23 levels had higher risks for ESA hyporesponsiveness.
In a phase 3 trial, difelikefalin, a kappa opioid receptor agonist, significant decreased itching and improved itching-related quality of life among dialysis patients suffering from pruritus.
In a study, spironolactone treatment was not significantly better than placebo in preventing diabetic nephropathy in patients with high-risk type 2 diabetes.
In a pooled analysis of data from 3 studies, patiromer lowered potassium levels into a target range of 3.8 to 5.0 mEq/L in 92.5% and 96.8% of patients with baseline potassium levels of 6.0 mEq/L or higher and less than 6.0 mEq/L, respectively.
In a study, 43.8% of hospitalized patients had sepsis and 48.8% had fluid overload requiring continuous renal replacement therapy.
In a study, patients with severe secondary hyperparathyroidism appeared to benefit the most from surgery.
Younger age, female sex, and lower serum creatinine are among the variables most strongly associated with recovery of kidney function following initiation of outpatient hemodialysis for acute kidney injury, a study found.
Users of selective serotonin reuptake inhibitors had a higher risk of hyponatremia than users of serotonin-norepinephrine reuptake inhibitors, especially with concurrent thiazide diuretic treatment.
Intradialytic hypotension (IDH) occurring in 30% or more of hemodialysis sessions is associated with a 36% increased likelihood of peripheral artery disease compared with no IDH, according to a new study.
Discontinuing angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy more than doubles the risk of death and dialysis initiation, according to a new study.